Predicting rectal cancer treatment response and side effects
Part of Cancer, Digestive system clinical trials.
This study uses metabolomics (analysis of small molecules in your body) to predict how well your rectal cancer will respond to treatment and whether you may experience side effects. It focuses on patients receiving total neoadjuvant therapy (treatment before surgery).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma (a common type) of the rectum.
- You are scheduled to receive total neoadjuvant therapy (a combination of chemotherapy and radiation before surgery).
- You have not had radiation therapy to the pelvic area before.
- You do not have inflammatory bowel disease (like Crohn's disease or ulcerative colitis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new way to predict how well your rectal cancer will respond to treatments given before surgery. It uses advanced tests (like looking at genes and other markers) to tailor your care.
This study looks at patterns in the gut microbiome (gut bacteria) and gut chemicals (metabolites) to predict how rectal cancer may do after planned surgery. By understanding these markers, researchers hope to better forecast prognosis and tailor follow-up.
This study uses advanced MRI scanning and computer analysis to predict how well rectal cancer might respond to treatments given before surgery. It may help doctors choose the best approach for you.
This study looks at how well rectal cancer responds to chemotherapy and radiation before surgery. It uses a genetic test on tumor tissue to predict whether the treatment will work for you.
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
Hear when a new Rectal Neoplasm Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.